SCHEMBL396159

SCHEMBL396159

CCN(CC)C(C(N)=O)n1c(C)c(C(=O)O)c(C)c1C=C1C(=O)Nc2cc(NC(=O)Nc3cc(NC(=O)c4ccccc4)ccc3C)ccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 12/20 0.47
▸ FLT4 P35916 9/20 0.47
▸ KDR P35968 8/20 0.47
▸ KIT P10721 7/20 0.47
▸ AURKB Q96GD4 6/20 0.42
▸ NTRK1 P04629 3/20 0.41
▸ CSF1R P07333 3/20 0.41
▸ PDGFRB P09619 2/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ ABL1 P00519 1/20 0.41
▸ INSR P06213 1/20 0.41
▸ LYN P07948 1/20 0.41
▸ RET P07949 1/20 0.41
▸ IGF1R P08069 1/20 0.41
▸ MET P08581 1/20 0.41
▸ ROS1 P08922 1/20 0.41
▸ FGR P09769 1/20 0.41
▸ SRC P12931 1/20 0.41
▸ FLT1 P17948 1/20 0.41
▸ FGFR4 P22455 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL393970 0.95 NTRK1 (0.44) FLT3FLT4KDRKITAURKB
SCHEMBL399058 0.94 FLT3 (0.48) FLT3FLT4KDRKITAURKB
SCHEMBL394525 0.93 FLT3 (0.51) FLT3FLT4KDRKITAURKB
SCHEMBL394110 0.93 FLT3 (0.48) FLT3FLT4KDRKITAURKB
SCHEMBL396850 0.90 NTRK1 (0.53) FLT3FLT4KDRKITAURKB
SCHEMBL399277 0.89 TLK2 (0.47) NTRK1RETTLK2AURKA
SCHEMBL397868 0.87 NTRK1 (0.52) FLT3KDRKITNTRK1CSF1R
SCHEMBL397245 0.86 MAPK14 (0.37) FLT3FLT4KDRKITAURKB
SCHEMBL394231 0.86 FLT3 (0.50) FLT3FLT4KDRKITAURKB
SCHEMBL395945 0.85 NTRK1 (0.51) FLT3FLT4KDRKITAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US disclosed
Send feedback